

Preprint

Relationship between the concentration of ergothioneine in plasma and the likelihood of developing pre-eclampsia

Louise C. Kenny¹, on behalf of the SCOPE Consortium, Leslie W Brown², Paloma Ortea², Robin Tuytten², and Douglas B. Kell^{3,4,*}

¹ Department of Women's and Children's Health, Faculty of Health and Life Sciences, University of Liverpool, Liverpool L7 8TX, UK.

² Metabolomic Diagnostics, Cork, Ireland; robin.tuytten@metabolomicdiagnostics.com

³ Dept of Biochemistry and Systems Biology, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Crown St, Liverpool L69 7BX; dbk@liv.ac.uk

⁴ The Novo Nordisk Foundation Centre for Biosustainability, Technical University of Denmark, Kemitorvet 200, 2800 Kgs Lyngby, Denmark

* Correspondence: dbk@liv.ac.uk

Abstract: Ergothioneine, an antioxidant nutraceutical mainly at present derived from the dietary intake of mushrooms, has been suggested as a preventive for pre-eclampsia. We analysed early pregnancy samples for a cohort of 432 first time mothers as part of the Screening for Endpoints in Pregnancy (SCOPE, European branch) project to determine the concentration of ergothioneine in their plasma. There was a weak association between the ergothioneine levels and maternal age, but none for BMI. Of these 432 women, 97 went on to develop pre-term (23) or term (74) pre-eclampsia. If a threshold was set at the 90th percentile of the reference range in the control population (≥ 462 ng/mL), only one of these 97 women (1%) developed pre-eclampsia, versus 97/432 (22.5%) whose ergothioneine level was below this threshold. One possible interpretation of these findings, consistent with previous experiments in a reduced uterine perfusion model in rats, is that ergothioneine may indeed prove protective against pre-eclampsia in humans. An intervention study of some kind now seems warranted.

Keywords: pre-eclampsia; prevention; ergothioneine; metabolomics; nutraceutical; mushrooms



Copyright: © 2022 by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Pre-eclampsia (PE) is a multi-system disorder of pregnancy, characterized by gestational hypertension and the new-onset of proteinuria and/or another maternal organ dysfunction [1-3]. It is widely considered to develop in two stages [4] [5]: an initial poor placentation [6] followed by oxidative stress and inflammation [7, 8]. As with many other chronic, inflammatory diseases [9], there is also substantial evidence for the involvement of a microbial component [10, 11]. PE can affect 3-5% of pregnancies worldwide [12], and has the potential to be life-threatening; the only real clinical recourse currently available the premature delivery of the fetus. Early markers for predicting pre-eclampsia are thus highly desirable.

Although some soluble protein markers such as sFlt1 and PlGF have proven to be of value (e.g. [13, 14]), a number of studies have developed the idea that small molecules (i.e. metabolomics [15, 16]) have the potential to provide both diagnostic information, and, via mechanistic reasoning, potentially treatments [17-29].

Ergothioneine is an important antioxidant nutraceutical (commonly derived from the dietary intake of mushrooms) [30-34], for which humans have evolved at least one transporter [35, 36]. In a large scale metabolomics study [37], it was by some distance the molecule most associated with the prevention of adverse cardiovascular outcomes. Its levels have also been linked with lowered incidences of cognitive defects [38], and it

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

prevented some of the main symptoms in the rat RUPP model of pre-eclampsia [39]. In view of the above, and its status as a potent antioxidant, it was thus considered plausible to have some utility in the prevention and/or diagnosis of PE in humans [40].

The international Screening for Pregnancy Endpoints (SCOPE) study [25, 41-43] (<http://scopestudy.net>) bio-banked early pregnancy blood samples from a large cohort of first time pregnant women, 4.9% whom developed pre-eclampsia as defined [44] by the International Society of the Study of Hypertension in Pregnancy [41]. Pre-term pre-eclampsia was defined as disease necessitating delivery before 27 weeks' gestation. The SCOPE study therefore provided the opportunity to assess whether there was any relation between their levels of ergothioneine and the likelihood of developing early or late-onset pre-eclampsia. The present study reports on a secondary analysis of ergothioneine levels in a previously reported case-control study assessing a panel of metabolite biomarker candidates for pre-eclampsia risk assessment at 15 +/-1 week of gestation [25]. Women with the highest level of ergothioneine had a significantly reduced likelihood of developing either preterm or term pre-eclampsia. One interpretation of such data could be that dietary supplementation with ergothioneine in pregnancy may reduce pre-eclampsia risk, and this is obviously now worth testing.

2. Results

2.1. Overall summary of the cohort studied

The nested Case-Control study was defined in the SCOPE – Europe cohort as described fully in [25], and the demographics (Table 1 of [25]) are not repeated here. For this work, we leveraged calibration data available in the previous study to estimate the ergothioneine blood levels (ng/mL) in 432 women of whom 335 did not develop PE, 23 suffered preterm PE, and 74 suffered from term PE.

2.2 Ergothioneine levels in the study population

In Figure 1 the distribution of ergothioneine levels in the study-subjects are plotted.




Figure 1. Distribution of ergothioneine levels in the study population.

The levels range from ~140 ng/ml to 998 ng/ml, with a median level of ~260 ng/ml. From Figure 1, it is clear that ergothioneine levels are not normally distributed within the study population, but that the long-tailed distribution is skewed to higher concentrations.

The distribution of ages may be observed in Figure 2, where it may also be seen that there was a weak yet significant correlation of ergothioneine levels with age ($r^2 = 0.08$; $p < 0.0001$). However, there was no significant relationship ($r = -0.07$; $p = 0.14$) between ergothioneine levels and BMI (Figure 3).




Figure 2. Relationship between ergothioneine level and maternal age.




Figure 3. Lack of relationship between ergothioneine level and BMI. Data have been jittered in the x-axis direction for clarity

2.3. Levels of ergothioneine in control and in preclamptic women

A chief finding here is illustrated in Fig 4, where we show the relationship between the levels of ergothioneine and whether the women concerned developed pre-eclampsia, whether at term or pre-term. Taking a threshold of >462 ng/mL, which is equivalent to the 90th percentile in the control population, we see that only 1/74 developed PE at term, and 0/23 developed PE pre-term, i.e. only 1/97 (1%) when these numbers are combined developed any form of PE. 33/335 (10%) who did not develop PE were also above this threshold. In other words, only a single individual out of 432 examples both had a level of ergothioneine above 462 ng/mL and developed any form of PE.

The ergothioneine levels for those three classes are given in Table 1, where it is clear that without considering the specific distributions in detail the mean and median figures would not have indicated an association between ergothioneine and pre-eclampsia risk. From the distributions as plotted in Fig 4 it can be inferred that within the study population, there is sub-set of study participants who have markedly higher ergothioneine blood levels, giving rise to a bimodal distribution within the study population.

The relationship shown in Figure 4 (i.e. setting a cut-off at the 90th centile) was post-hoc, yet it should be evident that a data-driven, machine learning analysis (to be contrasted with a frequentist statistical approach [45, 46]) would have discovered it, much as it did [22] in our first foray into pre-eclampsia metabolomics (using a low-resolution mass spectrometer that – as is still common even with high-resolution instruments [47-50] – could not identify most peaks of interest). We also note that reference-range-based rules are commonly used in clinical diagnostics to identify a population of interest, whereby patients with blood levels of a marker of interest in e.g. the top or bottom 10% of the reference interval are flagged.

Using the above 90th centile as a threshold to identify a population of interest, the following Odds Ratio for developing pre-eclampsia is found in this group; OR = 0.095 with 95% Confidence Interval (0.0129 to 0.706) and significance level $p < 0.02$.

Pregnancy Outcome	No Pre-eclampsia	Preterm Pre-eclampsia	Term Pre-eclampsia
N	335	23	74
Ergothioneine (ng/ml)			
Min – Max	140 – 998	149 – 383	166 – 497
Mean (95% CI)	294 (281 – 307)	259 (234 – 294)	276 (259 – 293)
Median (95% CI)	260 (248 – 271)	268 (230 – 288)	260 (247 – 282)
Standard Deviation	123	58	73
25-75 th Percentile (IQR)	211 – 332	214 – 290	220 – 333
10-90 th Percentile	184 – 462	183 – 340	188 – 382
Normal Distribution (p)*	< 0.0001	0.34	0.13

Table 1. Frequentist statistical analysis of the three pregnancy outcome classes here considered; * Shapiro-Wilk test; $p < 0.05$: Reject Normality; IQR: Inter Quartile Range; 95% CI: 95% Confidence interval

Relationship between ergothioneine level and pre - eclampsia class




Figure 4. Relationship between ergothioneine level and pre-eclampsia category. Data have been jittered in the y-axis direction for clarity

134
135




Figure 5. Violin plots based on individual measurements; --- median levels; blue line- 90th centile based on ergothioneine distribution in the control population. Data as in Figure 4 with statistical summary in Table 1.

136
137

3. Discussion

140

Stimulated by the recognition that ergothioneine might be a potentially useful therapeutic in PE [39, 40], and that it is certainly a potent (and safe [51]) antioxidant nutraceutical [30, 32-34, 52-59], we assessed its concentration in early pregnancy in a representative sample of 1st time pregnant women who participated in the European branch of the

141
142
143
144

SCOPE project. Certainly the range of concentrations observed was substantial, from an estimated ~ 140 ng/ml up to 1 µg/ml (Fig 3). Within the study population, the median levels were found to be non-differential between women who developed preterm-, term-pre-eclampsia or women who did not develop pre-eclampsia later in pregnancy. However, within the women who had ergothioneine levels \geq the 90th percentile of the reference population, i.e., women who did not develop pre-eclampsia, only one study participant developed pre-eclampsia.

The levels of ergothioneine reflect both intake (especially from mushrooms [60, 61]) and the activity of the various ergothioneine transporters [35, 36, 62-64], and neither of these were either known or controlled. Thus, as with a related study on cardiovascular event incidence, where ergothioneine was strongly (indeed the molecule most strongly) associated with more favourable outcomes in terms of morbidity and mortality [37], this was a purely observational study. Ergothioneine was also the metabolite associated with the lowest hazard ratio for all-cause mortality [65], and had the third highest loading in a signature collection of healthy metabolites [66]. Mushroom consumption is also strongly associated with a lowering of all-cause mortality [67] and of the incidence of mild cognitive impairment [68]. Consequently, since certain aspects of the pre-eclampsia syndrome share hallmarks of vascular disease [69-71], this study adds weight to the idea that it might be a useful nutraceutical in the prevention of (cardio)vascular diseases more generally.

4. Materials and Methods

Ergothioneine was one of the compounds analysed with multiplex targeted liquid chromatography – tandem mass spectrometry assay for pre-eclampsia biomarker candidates as detailed in [25]. In the latter study, biomarker levels were expressed as relative concentrations whereby for any sample the target metabolite read-out was divided by the read-out as obtained from a stable-isotope labelled metabolite internal standard spiked in equal amounts across all samples. Deuterated ergothioneine (D9) served as the stable-isotope labelled metabolite internal standard for ergothioneine quantification.

For this secondary data analysis, the relative ergothioneine concentrations were converted in estimated blood levels (ng/ml) using the calibrators co-analysed with the patient samples [25].

In brief, calibration curves were generated by means of firstly fortifying a pooled plasma (Technopath plasma with 2% K2-EDTA anticoagulant Lot PF-05171, Technopath, Ireland) with the metabolites of interest and then serially diluting the fortified sample with PBS/BSA buffer (0.01M phosphate buffer and 0.5% Albumin). The metabolites levels for the fortified matrix as well as the concentration span were estimated based on preliminary evaluations. This led to the creation of an 8-point calibration curve for all metabolites spanning a ~20-fold dynamic range. (CAL1; relative level = 100 to CAL8, relative level = 5.83). In a separate experiment the levels of ergothioneine in the pooled plasma were determined by means of standard addition [72], yielding an estimated level of 138 ng/ml. Using this information, the ergothioneine calibration range expressed in ng/mL is easily derived (174 ng/ml (CAL8) – 752 ng/ml (CAL1)). It is noted that said calibration range covers 93.5% of all patient samples assessed; moreover, we typically find that the linear range extends beyond the set calibration range for the metabolites assessed. Verification that the ergothioneine calibrator curves effectively mitigated technical variability followed the estimation of imprecision from the analysis of 73 duplicate patient samples (independently prepared and randomly distributed across study batches) using the method of Hyslop and White [73], returning a satisfactory Coefficient of Variation (%) = 11.5%.

Conclusions

The very striking observation that, in this cohort, only 1 individual out of 97 (1%) women with an ergothioneine level above 462 ng/ml manifested pre-eclampsia, whereas in the total cohort 97/432 (22.5%) did, demands an explanation. The easiest one is that this molecule is significantly protective towards (and may be consumed during) the

development of pre-eclampsia. It is worth noting that, as well as its occurrence in all known culinary mushrooms, ergothioneine is an available nutritional supplement, whose safety has been well established [51, 74-77]. Such an analysis will best be done via a randomized controlled trial.

Author Contributions: Conceptualization, DK, LK and RT; analytical methodology, LB, PO & RT; formal analysis, DK, RT.; investigation, LB, PO, RT, DK; resources; data curation, LK, PO & RT.; writing—original draft preparation, DK, RT & LB; writing—review and editing, DK, RT & LK.; funding acquisition, LK & RT. All authors have read and agreed to the published version of the manuscript.

Funding: This study received funding from the EU-HEALTH Project IMPROVED (305169) of the Seventh Framework Programme, the goal of IMPROVED is to develop a clinically robust predictive blood test for pre-eclampsia. SCOPE was funded by the New Enterprise Research Fund, Foundation for Research Science and Technology; Health Research Council; and Evelyn Bond Fund, Auckland District Health Board Charitable Trust (New Zealand); Premier’s Science and Research Fund, South Australian Government (Australia); and Health Research Board (Ireland). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. DBK is supported by the Novo Nordisk Foundation (grant NNF20CC0035580).

Institutional Review Board Statement: As described [25], Ethics approval was gained from local ethics committees of each participating centre (Manchester, Leeds, and London 06/MRE01/98, Cork ECM5 (10) 05/02/08). Collection of data and biological samples complied with standardised procedures in all participating centres and was conducted in accordance with the principles of the Declaration of Helsinki.

Informed Consent Statement: Written informed consent was obtained from all participants.

Acknowledgments: The investigators thank the pregnant women who participated in the SCOPE study for their indispensable contribution.

Conflicts of Interest: DBK is a named inventor on a patent (WO2020221795) describing the production of ergothioneine in yeast. Leslie W. Brown, Paloma Ortea and Robin Tuytten are employees of Metabolomic Diagnostics, and they and Louise C. Kenny are minority shareholders of Metabolomic Diagnostics. Leslie W. Brown, Robin Tuytten, and Louise C. Kenny are named inventors on a Patent Application which discloses the use of specific proteins and metabolites to predict pre-eclampsia risk, and which is assigned to Metabolomic Diagnostics, i.e., "Methods of predicting pre term birth from pre-eclampsia using metabolic and protein biomarkers", with publication number WO2019155075A1.

References

1. Magee, L. A.; Pels, A.; Helewa, M.; Rey, E.; von Dadelszen, P.; Canadian Hypertensive Disorders of Pregnancy Working Group, Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy. *Pregnancy Hypertens* **2014**, *4*, (2), 105-45.
2. Rich-Edwards, J. W.; Ness, R. B.; Roberts, J. M., Epidemiology of Pregnancy-Related Hypertension. *Chesley's Hypertensive Disorders in Pregnancy, 4th Edition* **2015**, 37-55.
3. Phipps, E. A.; Thadhani, R.; Benzing, T.; Karumanchi, S. A., Pre-eclampsia: pathogenesis, novel diagnostics and therapies. *Nat Rev Nephrol* **2019**, *15*, (5), 275-289.
4. Redman, C. W. G.; Sargent, I. L., Placental stress and pre-eclampsia: a revised view. *Placenta* **2009**, *30* Suppl A, S38-42.
5. Redman, C. W.; Sargent, I. L.; Staff, A. C., IFPA Senior Award Lecture: making sense of pre-eclampsia - two placental causes of preeclampsia? *Placenta* **2014**, *35* Suppl, S20-5.
6. Roberts, D. J.; Post, M. D., The placenta in pre-eclampsia and intrauterine growth restriction. *J Clin Pathol* **2008**, *61*, (12), 1254-60.
7. Braekke, K.; Harsem, N. K.; Staff, A. C., Oxidative stress and antioxidant status in fetal circulation in preeclampsia. *Pediatr Res* **2006**, *60*, (5), 560-4.
8. Manna, S.; Ruano, C. S. M.; Hegenbarth, J. C.; Vaiman, D.; Gupta, S.; McCarthy, F. P.; Mehats, C.; McCarthy, C.; Apicella, C.; Scheel, J., Computational Models on Pathological Redox Signalling Driven by Pregnancy: A Review. *Antioxidants (Basel)* **2022**, *11*, (3).
9. Kell, D. B.; Pretorius, E., No effects without causes. The Iron Dysregulation and Dormant Microbes hypothesis for chronic, inflammatory diseases. *Biol Rev* **2018**, *93*, 1518-1557.
10. Kell, D. B.; Kenny, L. C., A dormant microbial component in the development of pre-eclampsia. *Front Med Obs Gynecol* **2016**, *3*, 60.
11. Kenny, L. C.; Kell, D. B., Immunological tolerance, pregnancy and pre-eclampsia: the roles of semen microbes and the father. *Front Med Obs Gynecol* **2018**, *4*, 239.
12. Mol, B. W. J.; Roberts, C. T.; Thangaratinam, S.; Magee, L. A.; de Groot, C. J. M.; Hofmeyr, G. J., Pre-eclampsia. *Lancet* **2016**, *387*, (10022), 999-1011.
13. Powers, R. W.; Jeyabalan, A.; Clifton, R. G.; Van Dorsten, P.; Hauth, J. C.; Klebanoff, M. A.; Lindheimer, M. D.; Sibai, B.; Landon, M.; Miodovnik, M.; Eunice Kennedy Shriver Natl Inst of Child Health Human Development Maternal-Fetal Medicine Units Network, Soluble fms-Like Tyrosine Kinase 1 (sFlt1), Endoglin and Placental Growth Factor (PlGF) in Preeclampsia among High Risk Pregnancies. *Plos One* **2010**, *5*, (10).
14. Zeisler, H.; Llurba, E.; Chantraine, F.; Vatish, M.; Staff, A. C.; Sennstrom, M.; Olovsson, M.; Brennecke, S. P.; Stepan, H.; Allegranza, D.; Dilba, P.; Schoedl, M.; Hund, M.; Verlohren, S., Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia. *N Engl J Med* **2016**, *374*, (1), 13-22.
15. Oliver, S. G.; Winson, M. K.; Kell, D. B.; Baganz, F., Systematic functional analysis of the yeast genome. *Trends Biotechnol* **1998**, *16*, (9), 373-378.

16. Kell, D. B.; Oliver, S. G., The metabolome 18 years on: a concept comes of age. *Metabolomics* **2016**, 12, (9), 148. 267
17. Austdal, M.; Tangeras, L. H.; Skråstad, R. B.; Salvesen, K.; Austgulen, R.; Iversen, A. C.; Bathen, T. F., First Trimester Urine 268
and Serum Metabolomics for Prediction of Preeclampsia and Gestational Hypertension: A Prospective Screening Study. 269
Int J Mol Sci **2015**, 16, (9), 21520-38. 270
18. Bahado-Singh, R. O.; Akolekar, R.; Mandal, R.; Dong, E.; Xia, J.; Kruger, M.; Wishart, D. S.; Nicolaides, K., Metabolomics 271
and first-trimester prediction of early-onset preeclampsia. *J Matern Fetal Neonatal Med* **2012**, 25, (10), 1840-7. 272
19. Chen, T. T.; He, P.; Tan, Y.; Xu, D. Y., Biomarker identification and pathway analysis of preeclampsia based on serum 273
metabolomics. *Biochem Bioph Res Co* **2017**, 485, (1), 119-125. 274
20. Dessì, A.; Marincola, F. C.; Fanos, V., Metabolomics and the great obstetrical syndromes - GDM, PET, and IUGR. *Best Pract 275
Res Cl Ob* **2015**, 29, (2), 156-164. 276
21. Kelly, R. S.; Giorgio, R. T.; Chawes, B. L.; Palacios, N. I.; Gray, K. J.; Mirzakhani, H.; Wu, A.; Blighe, K.; Weiss, S. T.; Lasky- 277
Su, J., Applications of metabolomics in the study and management of preeclampsia: a review of the literature. 278
Metabolomics **2017**, 13, (7). 279
22. Kenny, L. C.; Dunn, W. B.; Ellis, D. I.; Myers, J.; Baker, P. N.; The GOPEC Consortium; Kell, D. B., Novel biomarkers for 280
pre-eclampsia detected using metabolomics and machine learning. *Metabolomics* **2005**, 1, (3), 227-234 - online DOI: 281
10.1007/s11306-005-0003-1. 282
23. Kenny, L. C.; Broadhurst, D.; Brown, M.; Dunn, W. B.; Redman, C. W. G.; Kell, D. B.; Baker, P. N., Detection and 283
identification of novel metabolomic biomarkers in preeclampsia. *Reprod Sci* **2008**, 15, (6), 591-7. 284
24. Kenny, L. C.; Broadhurst, D. I.; Dunn, W.; Brown, M.; Francis-McIntyre, S.; North, R. A.; McGowan, L.; Roberts, C.; 285
Cooper, G. J. S.; Kell, D. B.; Philip N Baker on behalf of the SCOPE consortium, Robust early pregnancy prediction of later 286
preeclampsia using metabolomic biomarkers *Hypertension* **2010**, 56, 741-749. 287
25. Kenny, L. C.; Thomas, G.; Poston, L.; Myers, J. E.; Simpson, N. A. B.; McCarthy, F. P.; Brown, L. W.; Bond, A. E.; Tuytten, 288
R.; Baker, P. N.; Screening for Pregnancy Endpoints Consortium, Prediction of preeclampsia risk in first time pregnant 289
women: Metabolite biomarkers for a clinical test. *PLoS One* **2020**, 15, (12), e0244369. 290
26. Koster, M. P. H.; Vreeken, R. J.; Harms, A. C.; Dane, A. D.; Kuc, S.; Schielen, P. C. J. I.; Hankemeier, T.; Berger, R.; Visser, 291
G. H. A.; Pennings, J. L. A., First-Trimester Serum Acylcarnitine Levels to Predict Preeclampsia: A Metabolomics 292
Approach. *Dis Markers* **2015**, 2015, 857108. 293
27. Kuc, S.; Koster, M. P. H.; Pennings, J. L. A.; Hankemeier, T.; Berger, R.; Harms, A. C.; Dane, A. D.; Schielen, P. C. J. I.; 294
Visser, G. H. A.; Vreeken, R. J., Metabolomics profiling for identification of novel potential markers in early prediction of 295
preeclampsia. *PloS one* **2014**, 9, (5), e98540. 296
28. Nobakht, M. G. B. F., Application of metabolomics to preeclampsia diagnosis. *Syst Biol Reprod Med* **2018**, 64, (5), 324-339. 297
29. Woodham, P. C.; O'Connell, T.; Grimes, J.; Haeri, S.; Eichelberger, K.; Baker, A.; Boggess, K., Metabolomics to predict 298
severe preeclampsia in early pregnancy. *Am J Obstet Gynecol* **2012**, 206, (1), S348-S348. 299
30. Borodina, I.; Kenny, L. C.; McCarthy, C. M.; Paramasivan, K.; Pretorius, R.; Roberts, T. J.; van der Hoek, S. A.; Kell, D. B., 300
The biology of ergothioneine, an antioxidant nutraceutical. *Nutr Res Rev* **2020**, 33, 190-217. 301
31. Cheah, I. K.; Halliwell, B., Ergothioneine; antioxidant potential, physiological function and role in disease. *Biochim Biophys 302
Acta* **2012**, 1822, (5), 784-93. 303
32. Cheah, I. K.; Halliwell, B., Ergothioneine, recent developments. *Redox Biol* **2021**, 42, 101868. 304
33. Halliwell, B.; Cheah, I. K.; Tang, R. M. Y., Ergothioneine - a diet-derived antioxidant with therapeutic potential. *FEBS Lett 305
2018*, 592, 3357-3366. 306
34. Halliwell, B.; Cheah, I., Ergothioneine, where are we now? *FEBS Lett* **2022**, 596, (10), 1227-1230. 307
35. Gründemann, D.; Harlfinger, S.; Golz, S.; Geerts, A.; Lazar, A.; Berkels, R.; Jung, N.; Rubbert, A.; Schömig, E., Discovery of 308
the ergothioneine transporter. *Proc Natl Acad Sci* **2005**, 102, (14), 5256-61. 309

36. Gründemann, D.; Hartmann, L.; Flögel, S., The Ergothioneine Transporter (ETT): Substrates and Locations, an Inventory. *FEBS Lett* **2022**, 596, 1252-1269. 310
37. Smith, E.; Ottosson, F.; Hellstrand, S.; Ericson, U.; Orho-Melander, M.; Fernandez, C.; Melander, O., Ergothioneine is associated with reduced mortality and decreased risk of cardiovascular disease. *Heart* **2020**, 106, 691-697. 311
38. Wu, L. Y.; Kan, C. N.; Cheah, I. K.; Chong, J. R.; Xu, X.; Vrooman, H.; Hilal, S.; Venketasubramanian, N.; Chen, C. P.; Halliwell, B.; Lai, M. K. P., Low Plasma Ergothioneine Predicts Cognitive and Functional Decline in an Elderly Cohort Attending Memory Clinics. *Antioxidants (Basel)* **2022**, 11, (9). 312
39. Williamson, R. D.; McCarthy, F. P.; Manna, S.; Groarke, E.; Kell, D. B.; Kenny, L. C.; McCarthy, C. M., L-(+)-Ergothioneine Significantly Improves the Clinical Characteristics of Preeclampsia in the Reduced Uterine Perfusion Pressure Rat Model. *Hypertension* **2020**, 75, 561-568. 313
40. Kerley, R. N.; McCarthy, C.; Kell, D. B.; Kenny, L. C., The potential therapeutic effects of ergothioneine in pre-eclampsia. *Free radical biology & medicine* **2018**, 117, 145-157. 314
41. Kenny, L. C.; Black, M. A.; Poston, L.; Taylor, R.; Myers, J. E.; Baker, P. N.; McCowan, L. M.; Simpson, N. A. B.; Dekker, G. A.; Roberts, C. T.; Rodems, K.; Noland, B.; Raymundo, M.; Walker, J. J.; North, R. A., Early pregnancy prediction of preeclampsia in nulliparous women, combining clinical risk and biomarkers: the Screening for Pregnancy Endpoints (SCOPE) international cohort study. *Hypertension* **2014**, 64, (3), 644-52. 315
42. McCowan, L. M. E.; Thompson, J. M.; Taylor, R. S.; Baker, P. N.; North, R. A.; Poston, L.; Roberts, C. T.; Simpson, N. A.; Walker, J. J.; Myers, J.; Kenny, L. C.; SCOPE consortium, Prediction of Small for Gestational Age Infants in Healthy Nulliparous Women Using Clinical and Ultrasound Risk Factors Combined with Early Pregnancy Biomarkers. *PLoS One* **2017**, 12, (1), e0169311. 316
43. Vieira, M. C.; Poston, L.; Fyfe, E.; Gillett, A.; Kenny, L. C.; Roberts, C. T.; Baker, P. N.; Myers, J. E.; Walker, J. J.; McCowan, L. M.; North, R. A.; Pasupathy, D.; Scope Consortium, Clinical and biochemical factors associated with preeclampsia in women with obesity. *Obesity (Silver Spring)* **2017**, 25, (2), 460-467. 317
44. Brown, M. A.; Magee, L. A.; Kenny, L. C.; Karumanchi, S. A.; McCarthy, F. P.; Saito, S.; Hall, D. R.; Warren, C. E.; Adoyi, G.; Ishaku, S.; International Society for the Study of Hypertension in, P., Hypertensive Disorders of Pregnancy: ISSHP Classification, Diagnosis, and Management Recommendations for International Practice. *Hypertension* **2018**, 72, (1), 24-43. 318
45. Breiman, L., Statistical modeling: The two cultures. *Stat Sci* **2001**, 16, (3), 199-215. 319
46. Broadhurst, D.; Kell, D. B., Statistical strategies for avoiding false discoveries in metabolomics and related experiments. *Metabolomics* **2006**, 2, (4), 171-196. 320
47. Dunn, W. B.; Erban, A.; Weber, R. J. M.; Creek, D. J.; Brown, M.; Breitling, R.; Hankemeier, T.; Goodacre, R.; Neumann, S.; Kopka, J.; Viant, M. R., Mass Appeal: metabolite identification in mass spectrometry-focused untargeted metabolomics. *Metabolomics* **2013**, 9, S44-S66. 321
48. Wright Muelas, M.; Roberts, I.; Mughal, F.; O'Hagan, S.; Day, P. J.; Kell, D. B., An untargeted metabolomics strategy to measure differences in metabolite uptake and excretion by mammalian cell lines. *Metabolomics* **2020**, 16, 107. 322
49. Roberts, I.; Wright Muelas, M.; Taylor, J. M.; Davison, A. S.; Xu, Y.; Grixti, J. M.; Gotts, N.; Sorokin, A.; Goodacre, R.; Kell, D. B., Untargeted metabolomics of COVID-19 patient serum reveals potential prognostic markers of both severity and outcome. *Metabolomics* **2022**, 18, 6. 323
50. Shrivastava, A. D.; Swainston, N.; Samanta, S.; Roberts, I.; Wright Muelas, M.; Kell, D. B., MassGenie: a transformer-based deep learning method for identifying small molecules from their mass spectra. *Biomolecules* **2021**, 11, 1793. 324
51. Turck, D.; Bresson, J. L.; Burlingame, B.; Dean, T.; Fairweather-Tait, S.; Heinonen, M.; Hirsch-Ernst, K. I.; Mangelsdorf, I.; McArdle, H. J.; Naska, A.; Neuhauser-Berthold, M.; Nowicka, G.; Pentieva, K.; Sanz, Y.; Siani, A.; Sjodin, A.; Stern, M.; Tome, D.; Vinceti, M.; Willatts, P.; Engel, K. H.; Marchelli, R.; Poting, A.; Poulsen, M.; Schlatter, J.; Ackerl, R.; van Loveren, 325

H.; EFSA Panel Dietetic Prod Nutr, Safety of synthetic L-ergothioneine (Ergoneine (R)) as a novel food pursuant to Regulation (EC) No 258/97. *EFSA J* **2016**, 14, (11).

52. Ames, B. N., Prolonging healthy aging: longevity vitamins and proteins. *Proc Natl Acad Sci* **2018**, 115, (43), 10836-10844.

53. Beelman, R. B.; Kalaras, M. D.; Phillips, A. T.; Richie, J. P., Jr., Is ergothioneine a 'longevity vitamin' limited in the American diet? *J Nutr Sci* **2020**, 9, e52.

54. Beelman, R. B.; Phillips, A. T.; Richie, J. P., Jr.; Ba, D. M.; Duiker, S. W.; Kalaras, M. D., Health Consequences of Improving the Content of Ergothioneine in the Food Supply. *FEBS Lett* **2021**.

55. Lam-Sidun, D.; Peters, K. M.; Borradaile, N. M., Mushroom-Derived Medicine? Preclinical Studies Suggest Potential Benefits of Ergothioneine for Cardiometabolic Health. *Int J Mol Sci* **2021**, 22, (6).

56. Paul, B. D., Ergothioneine: A Stress Vitamin with Anti-Aging, Vascular and Neuroprotective Roles? *Antioxid Redox Signal* **2021**, 36, 16-18.

57. Fu, T. T.; Shen, L., Ergothioneine as a Natural Antioxidant Against Oxidative Stress-Related Diseases. *Front Pharmacol* **2022**, 13, 850813.

58. Whitmore, C. A.; Haynes, J. R.; Behof, W. J.; Rosenberg, A. J.; Tantawy, M. N.; Hachey, B. C.; Wadzinski, B. E.; Spiller, B. W.; Peterson, T. E.; Paffenroth, K. C.; Harrison, F. E.; Beelman, R. B.; Wijesinghe, P.; Matsubara, J. A.; Pham, W., Longitudinal Consumption of Ergothioneine Reduces Oxidative Stress and Amyloid Plaques and Restores Glucose Metabolism in the 5XFAD Mouse Model of Alzheimer's Disease. *Pharmaceuticals (Basel)* **2022**, 15, (6), 742.

59. Nakamichi, N.; Tsuzuku, S.; Shibagaki, F., Ergothioneine and central nervous system diseases. *Neurochem Res* **2022**, 47, (9), 2513-2521.

60. Dubost, N. J.; Beelman, R. B.; Peterson, D.; Royse, D. J., Identification and Quantification of Ergothioneine in Cultivated Mushrooms by Liquid Chromatography-Mass Spectroscopy. *Int J Med Mush* **2005**, 8, 215-222.

61. Kalaras, M. D.; Richie, J. P.; Calcagnotto, A.; Beelman, R. B., Mushrooms: A rich source of the antioxidants ergothioneine and glutathione. *Food Chem* **2017**, 233, 429-433.

62. Gründemann, D., The ergothioneine transporter controls and indicates ergothioneine activity--a review. *Prev Med* **2012**, 54 Suppl, S71-S74.

63. Cheah, I. K.; Ong, R. L.; Gruber, J.; Yew, T. S.; Ng, L. F.; Chen, C. B.; Halliwell, B., Knockout of a putative ergothioneine transporter in *Caenorhabditis elegans* decreases lifespan and increases susceptibility to oxidative damage. *Free Radic Res* **2013**, 47, (12), 1036-45.

64. Yee, S. W.; Buitrago, D.; Stecula, A.; Ngo, H. X.; Chien, H. C.; Zou, L.; Koleske, M. L.; Giacomini, K. M., Deorphaning a solute carrier 22 family member, SLC22A15, through functional genomic studies. *Faseb J* **2020**, 34, 15734-15752.

65. Yan, Y.; Smith, E.; Melander, O.; Ottosson, F., The association between plasma metabolites and future risk of all-cause mortality. *J Intern Med* **2022**.

66. Smith, E.; Ericson, U.; Hellstrand, S.; Orho-Melander, M.; Nilsson, P. M.; Fernandez, C.; Melander, O.; Ottosson, F., A healthy dietary metabolic signature is associated with a lower risk for type 2 diabetes and coronary artery disease. *BMC Med* **2022**, 20, (1), 122.

67. Ba, D. M.; Gao, X.; Muscat, J.; Al-Shaar, L.; Chinchilli, V.; Zhang, X.; Ssentongo, P.; Beelman, R. B.; Richie, J. P., Jr., Association of mushroom consumption with all-cause and cause-specific mortality among American adults: prospective cohort study findings from NHANES III. *Nutr J* **2021**, 20, (1), 38.

68. Feng, L.; Cheah, I. K.; Ng, M. M.; Li, J.; Chan, S. M.; Lim, S. L.; Mahendran, R.; Kua, E. H.; Halliwell, B., The association between mushroom consumption and Mild Cognitive Impairment: a community-based cross-sectional study in Singapore. *J Alzheimers Dis* **2019**, 68, 197-203.

69. Conti, E.; Zezza, L.; Ralli, E.; Caserta, D.; Musumeci, M. B.; Moscarini, M.; Autore, C.; Volpe, M., Growth factors in preeclampsia: a vascular disease model. A failed vasodilation and angiogenic challenge from pregnancy onwards? *Cytokine Growth Factor Rev* **2013**, 24, (5), 411-25.
70. Leon, L. J.; McCarthy, F. P.; Direk, K.; Gonzalez-Izquierdo, A.; Prieto-Merino, D.; Casas, J. P.; Chappell, L., Preeclampsia and Cardiovascular Disease in a Large UK Pregnancy Cohort of Linked Electronic Health Records: A CALIBER Study. *Circulation* **2019**, 140, (13), 1050-1060.
71. Vogel, B.; Acevedo, M.; Appelman, Y.; Bairey Merz, C. N.; Chieffo, A.; Figtree, G. A.; Guerrero, M.; Kunadian, V.; Lam, C. S. P.; Maas, A.; Mihailidou, A. S.; Olszanecka, A.; Poole, J. E.; Saldarriaga, C.; Saw, J.; Zuhlke, L.; Mehran, R., The Lancet women and cardiovascular disease Commission: reducing the global burden by 2030. *Lancet* **2021**, 397, (10292), 2385-2438.
72. Kruve, A.; Rebane, R.; Kipper, K.; Oldekop, M. L.; Evard, H.; Herodes, K.; Ravio, P.; Leito, I., Tutorial review on validation of liquid chromatography-mass spectrometry methods: part II. *Anal Chim Acta* **2015**, 870, 8-28.
73. Hyslop, N. P.; White, W. H., Estimating precision using duplicate measurements. *J Air Waste Manag Assoc* **2009**, 59, (9), 1032-9.
74. Schauss, A. G.; Vértési, A.; Endres, J. R.; Hirka, G.; Clewell, A.; Qureshi, I.; Pasics, I., Evaluation of the safety of the dietary antioxidant ergothioneine using the bacterial reverse mutation assay. *Toxicology* **2010**, 278, (1), 39-45.
75. Forster, R.; Spézia, F.; Papineau, D.; Sabadie, C.; Erdelmeier, I.; Moutet, M.; Yadan, J. C., Reproductive safety evaluation of L-Ergothioneine. *Food Chem Toxicol* **2015**, 80, 85-91.
76. Marone, P. A.; Trampota, J.; Weisman, S., A safety evaluation of a nature-identical L-ergothioneine in Sprague Dawley rats. *Int J Toxicol* **2016**, 35, (5), 568-83.
77. Turck, D.; Bresson, J. L.; Burlingame, B.; Dean, T.; Fairweather-Tait, S.; Heinonen, M.; Hirsch-Ernst, K. I.; Mangelsdorf, I.; McArdle, H. J.; Naska, A.; Neuhauser-Berthold, M.; Nowicka, G.; Pentieva, K.; Sanz, Y.; Siani, A.; Sjodin, A.; Stern, M.; Tome, D.; Vinceti, M.; Willatts, P.; Engel, K. H.; Marchelli, R.; Poting, A.; Poulsen, M.; Schlatter, J. R.; Ackerl, R.; van Loveren, H.; EFSA Panel Dietetic Prod Nutr, Statement on the safety of synthetic L-ergothioneine as a novel food - supplementary dietary exposure and safety assessment for infants and young children, pregnant and breastfeeding women. *EFSA J* **2017**, 15, (11).